Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
By P. Pappas, C. Kauffman, D. Andes, C. Clancy, K. Marr, L. Ostrosky-Zeichner, A. Reboli, M. Schuster, J. Vázquez, T. Walsh and 2 more. Clinical Infectious Diseases, 2016
1,198 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/6497da7b6d72e7a9ce420a154e528e0b26a01808
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species (2017, background): “The polyenes, azoles, echinocandins, nucleoside analogs, and allylamines are used with varying efficacy depending on the type and site of infection and the sensitivity of the Candida species (Pfaller et al., 2010; Pfaller and Diekema, 2012b; Pfaller et al., 2013; Pappas et al., 2016).”
- Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment (2017, background): “Expert guidelines have few evidence-based data to guide their recommendations [12, 69].”